Pays: États-Unis
Langue: anglais
Source: NLM (National Library of Medicine)
HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 (UNII: FKD3DUK39I) (HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 - UNII:FKD3DUK39I)
Teva Women's Health, Inc.
HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578
HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 32000 [TCID_50]
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should not be administered to pregnant females [See Pregnancy (8.1)] . It is not known whether Adenovirus Type 4 and Type 7 Vaccine, Live, Oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Naturally occurring infection with adenoviruses has been associated with fetal harm. Pregnancy should be avoided for 6 weeks following receipt of vaccine. Severe allergic reaction (e.g., anaphylaxis) to any component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a Contraindication [See Description (11)]. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral should not be administered to individuals incapable of swa
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Enteric Coated Tablets is packaged in a carton of two bottles of 100 tablets of each component of the vaccine: Store refrigerated between 2° and 8° C (35° and 46° F). Do not freeze. Keep bottle tightly closed and protect from moisture. Do not remove desiccant canister from bottle.
Biologic Licensing Application
ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE- ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE TEVA WOMEN'S HEALTH, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE, ORAL SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE, ORAL. ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE, ORAL ENTERIC COATED TABLETS FOR ORAL ADMINISTRATION INITIAL U.S. APPROVAL: 2011 INDICATIONS AND USAGE Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is approved for use in military populations 17 through 50 years of age. (1) DOSAGE AND ADMINISTRATION A single vaccine dose is administered orally as two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. (2) Each of the two tablets should be swallowed whole. The tablets should not be chewed or crushed to avoid releasing the live adenovirus in the upper respiratory tract. Postpone administration in vaccinees with vomiting and/or diarrhea. DOSAGE FORMS AND STRENGTHS A single oral dose consists of one Adenovirus Type 4 tablet and one Adenovirus Type 7 tablet. (3) CONTRAINDICATIONS Pregnancy (4.1, 8.1). Severe allergic reaction (e.g., anaphylaxis) to any component of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a Contraindication. (4.2, 11) Inability to swallow the tablets whole without chewing. (4.3) WARNINGS AND PRECAUTIONS Safety and effectiveness have not been evaluated in persons with primary or acquired immunodeficiency states. (5.1) Vaccinees and individuals who come in close contact with vaccinees may be exposed to the vaccine viruses shed in the stool for up to 28 days. Proper personal hygiene can minimize this risk. (5.2) Vaccinees should exercise caution when in close contact with children less than 7 years of a Lire le document complet